Nicole Mayer-Hamblett.

Frank J. Accurso, M.D http://www.clobetasocream.com/contact-us ., Steven M. Rowe, M.D., J.P. Clancy, M.D., Michael P. Boyle, M.D., Jordan M. Dunitz, M.D., Peter R. Durie, M.D., Scott D. Sagel, M.D., Douglas B. Hornick, M.D., Michael W. Konstan, M.D., Scott H. Donaldson, M.D., Richard B. Moss, M.D., Joseph M. Pilewski, M.D., Ronald C. Rubenstein, M.D., Ph.D., Ahmet Z. Uluer, D.O., Moira L. Aitken, M.D., Steven D. Freedman, M.D., Ph.D., Lynn M. Rose, Ph.D., Nicole Mayer-Hamblett, Ph.D., Qunming Dong, Ph.D., Jiuhong Zha, Ph.D., Anne J. Rock, B.A., Eric R. Olson, Ph.D., Claudia L.D., Preston W. Campbell, M.D., Melissa A. Ashlock, M.D., and Bonnie W. Ramsey, M.D.: Aftereffect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation Cystic fibrosis is usually a progressive lung disease1 due to mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator protein, an epithelial ion channel involved in salt and fluid transport in multiple organs, including the lung.